Correlation between cognitive impairment and serum neurofilament-light level in eldly patients with minor ischemic stroke

doi:10.3877/cma.j.issn.2095-123X.2021.06.008

Abstract

Abstract:

Objective

To investigate the relationship between serum neurofilament-light (NfL) level and post-stroke cognitive impairment 6 months after minor ischemic stroke (MIS) in eldly patients.

Methods

From March 2019 to June 2020, eldly patients with mild ischemic stroke who were admitted to the Neurology Department of Liaocheng People’s Hospital were prospectively enrolled. Serum NfL levels were measured by single molecule array. On the 6 months, all patients were divided into cognitive impairment group and cognitive normal group according to the score of Montreal cognitive assessment. The difference of serum NfL levels between the two groups was tested, and the relationship between the serum NfL level and cognitive impairment was statistically analyzed.

Results

Finally 113 elderly patients were included statistical analysis. At 6-month follow-up, 47 cases (41.6%) were diagnosed as post-stroke cognitive impairment (the cognitive impairment group), and the remaining 66 cases (58.4%) were the cognitive normal group. Compared with the cognitive normal group, the serum NfL level age, Fazekas score and the percentage of hypertension in the cognitive impairment group were all significantly higher (P<0.05). Multivariate logistic regression analysis showed that hypertension, Fazekas scale and serum NfL level were risk factors for cognitive impairment after MIS in the elderly (P<0.05).

Conclusion

For elderly patients with MIS, elevated serum neurofilament light levels are independent risk factors for cognitive impairment.

Key words: Minor ischemic stroke, Cognitive impairment, Serum neurofilament-light

Weifei Wang, Guangfeng Li, Xianbo Zhuang, Guanhua Yan. Correlation between cognitive impairment and serum neurofilament-light level in eldly patients with minor ischemic stroke[J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2021, 11(06): 358-361.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhnkjbykfzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-123X.2021.06.008

https://zhnkjbykfzz.cma-cmc.com.cn/EN/Y2021/V11/I06/358

Figures/Tables 3

References 19

[1]	Kapoor A, Lanctot KL, Bayley M, et al. Screening for post-stroke depression and cognitive impairment at baseline predicts long-term patient-centered outcomes after stroke[J]. J Geriatr Psychiatry Neurol, 2019, 32(1): 40-48.
[2]	Zetterberg H, Skillbäck T, Mattsson N, et al. Association of cerebrospinal fluid neurofilament light concentration with alzheimer disease progression[J]. JAMA Neurol, 2016, 73(1): 60-67.
[3]	Olsson B, Portelius E, Cullen NC, et al. Association of cerebrospinal fluid neurofilament light protein levels with cognition in patients with dementia, motor neuron disease, and movement disorders[J]. JAMA Neurol, 2019, 76(3): 318-325.
[4]	中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志, 2018, 51(9): 666-682.
[5]	Marques TM, van Rumund A, Oeckl P, et al. Serum NFL discriminates parkinson disease from atypical parkinsonisms[J]. Neurology, 2019, 92(13): e1479-e1486.
[6]	Li J, You SJ, Xu YN, et al. Cognitive impairment and sleep disturbances after minor ischemic stroke[J]. Sleep Breath, 2019, 23(2): 455-462.
[7]	Malojcic B, Giannakopoulos P, Sorond FA, et al. Ultrasound and dynamic functional imaging in vascular cognitive impairment and Alzheimer’s disease[J]. BMC Med, 2017, 15(1): 27.
[8]	邹永明，田志岩，张惠红, 等. 不同类型痴呆患者阿尔茨海默病相关神经丝蛋白水平和嗅觉功能差异的比较[J]. 中华老年医学杂志, 2018, 37(7): 738-742.
[9]	Pereira JB, Westman E, Hansson O, et al. Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer’s disease[J]. Neurobiol Aging, 2017, 58: 14-29.
[10]	Gaetani L, Blennow K, Calabresi P, et al. Neurofilament light chain as a biomarker in neurological disorders[J]. J Neurol Neurosurg Psychiatry, 2019, 90(8): 870-881.
[11]	彭丽君，钱海蓉，毛琳玲, 等. 神经丝蛋白轻链在视神经脊髓炎谱系疾病诊断和预后中的意义[J]. 中华神经科杂志, 2017, 50(6): 430-434.
[12]	Mattsson N, Cullen NC, Andreasson U, et al. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease[J]. JAMA Neurol, 2019, 76(7): 791-799.
[13]	van der Ende EL, Meeter LH, Poos JM, et al. Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study[J]. Lancet Neurol, 2019, 18(12): 1103-1111.
[14]	Novakova L, Zetterberg H, Sundström P, et al. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein[J]. Neurology, 2017, 89(22): 2230-2237.
[15]	Byrne LM, Rodrigues FB, Blennow K, et al. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington’s disease: a retrospective cohort analysis[J]. Lancet Neurol, 2017, 16(8): 601-609.
[16]	Weston PSJ, Poole T, Ryan NS, et al. Serum neurofilament light in familial Alzheimer disease: a marker of early neurodegeneration[J]. Neurology, 2017, 89(21): 2167-2175.
[17]	Gattringer T, Pinter D, Enzinger C, et al. Serum neurofilament light is sensitive to active cerebral small vessel disease[J]. Neurology, 2017, 89(20): 2108-2114.
[18]	Levine DA, Wadley VG, Langa KM, et al. Risk factors for poststroke cognitive decline: the REGARDS study (reasons for geographic and racial differences in stroke)[J]. Stroke, 2018, 49(4): 987-994.
[19]	Liang Y, Chen YK, Liu YL, et al. Cerebral small vessel disease burden is associated with accelerated poststroke cognitive decline: a 1-year follow-up study[J]. J Geriatr Psychiatry Neurol, 2019, 32(6): 336-343.

组别	例数	年龄（岁，Mean±SD）	男性[例（%）]	吸烟[例（%）]	饮酒[例（%）]	高血压[例（%）]	糖尿病[例（%）]	高脂血症[例（%）]	Fazeka评分[分，M（QR）]	NIHSS评分[分，M（QR）]	NfL（pg/mL，Mean±SD）
认知正常组	66	68.9±7.2	35（53.0）	17（25.8）	20（30.3）	34（51.5）	26（39.4）	28（42.4）	2.0（2.0）	1.5（3.0）	55.32±12.41
认知障碍组	47	74.2±10.3	28（59.6）	14（29.8）	12（25.5）	36（76.6）	21（44.7）	19（40.4）	3.0（3.0）	2.0（3.0）	73.84±19.25
t/χ²/Z值		3.061	0.028	0.405	1.014	5.806	0.003	0.011	3.488	0.367	3.460
P值		0.003	0.896	0.536	0.375	0.018	0.952	0.924	<0.001	0.592	0.001

组别	例数	年龄（岁，Mean±SD）	男性[例（%）]	吸烟[例（%）]	饮酒[例（%）]	高血压[例（%）]	糖尿病[例（%）]	高脂血症[例（%）]	Fazeka评分[分，M（QR）]	NIHSS评分[分，M（QR）]	NfL（pg/mL，Mean±SD）
认知正常组	66	68.9±7.2	35（53.0）	17（25.8）	20（30.3）	34（51.5）	26（39.4）	28（42.4）	2.0（2.0）	1.5（3.0）	55.32±12.41
认知障碍组	47	74.2±10.3	28（59.6）	14（29.8）	12（25.5）	36（76.6）	21（44.7）	19（40.4）	3.0（3.0）	2.0（3.0）	73.84±19.25
t/χ²/Z值		3.061	0.028	0.405	1.014	5.806	0.003	0.011	3.488	0.367	3.460
P值		0.003	0.896	0.536	0.375	0.018	0.952	0.924	<0.001	0.592	0.001

组别	例数	视空间与执行能力	命名	注意与计算力	语言	抽象能力	延迟记忆	定向力
认知正常组	66	4.56±0.43	2.89±0.32	5.52±0.48	2.74±0.22	1.89±0.14	4.37±0.46	5.81±0.33
认知障碍组	47	3.67±0.35	2.87±0.31	5.06±0.36	2.61±0.18	1.42±0.25	3.18±0.61	5.77±0.30
t值		2.714	0.612	2.139	0.750	2.187	3.035	0.402
P值		0.007	0.536	0.042	0.446	0.035	0.004	0.731

组别	例数	视空间与执行能力	命名	注意与计算力	语言	抽象能力	延迟记忆	定向力
认知正常组	66	4.56±0.43	2.89±0.32	5.52±0.48	2.74±0.22	1.89±0.14	4.37±0.46	5.81±0.33
认知障碍组	47	3.67±0.35	2.87±0.31	5.06±0.36	2.61±0.18	1.42±0.25	3.18±0.61	5.77±0.30
t值		2.714	0.612	2.139	0.750	2.187	3.035	0.402
P值		0.007	0.536	0.042	0.446	0.035	0.004	0.731

自变量	回归系数	标准误	Wald值	OR值	95%CI	P值
高血压	1.024	1.275	3.151	2.516	1.195~8.263	0.038
Fazeka评分	0.869	1.161	7.041	1.824	1.337~3.290	0.004
血清NfL	1.328	0.947	4.267	1.216	1.016~2.382	0.016

Please choose a citation manager

Content to export